Cellular Biomedicine Group Inc (NASDAQ:CBMG) insider Yihong Yao bought 4,167 shares of Cellular Biomedicine Group stock in a transaction dated Friday, December 22nd. The shares were bought at an average price of $12.00 per share, for a total transaction of $50,004.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Cellular Biomedicine Group Inc (NASDAQ:CBMG) traded down $0.25 during mid-day trading on Thursday, hitting $10.30. 29,000 shares of the stock were exchanged, compared to its average volume of 33,461. Cellular Biomedicine Group Inc has a 12 month low of $5.05 and a 12 month high of $13.80. The firm has a market capitalization of $146.41, a price-to-earnings ratio of -5.95 and a beta of 2.82.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Cellular Biomedicine Group during the third quarter worth approximately $107,000. Susquehanna International Group LLP bought a new stake in shares of Cellular Biomedicine Group during the second quarter worth approximately $320,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Cellular Biomedicine Group during the second quarter worth approximately $540,000. 4.03% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/28/cellular-biomedicine-group-inc-cbmg-insider-yihong-yao-acquires-4167-shares.html.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.